Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Time Is The Charm For Thalomid Myeloma Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved Celgene’s sNDA for the oncology indication after issuing two “approvable” letters.

You may also be interested in...



Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.

Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.

Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.

Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.

Related Content

Topics

UsernamePublicRestriction

Register

PS064226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel